Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211897 · ClinicalTrials.gov registry record
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
A clinical trial of Agitation,Psychomotor, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- 737
- Enrollment target
- 1
- Study location
NCT03211897 is a study of Agitation,Psychomotor that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 737 participants, above the 152-participant average among 4 other Agitation,Psychomotor trials with a reported enrollment target (385% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03211897, a study of Agitation,Psychomotor, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- 737 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research investigation is to conduct a prospective observational study of the comparative efficacy of haloperidol versus olanzapine versus midazolam versus ziprasidone for the treatment of acute undifferentiated agitation in the emergency department.
Conditions Studied
Interventions
- DRUG Haloperidol Injection
- DRUG Ziprasidone Injection
- DRUG OLANZapine Injection
- DRUG Midazolam injection
Study Locations (1)
Minnesota
- Hennepin County Medical Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 737 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2017-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211897
The ClinicalTrials.gov registry entry for NCT03211897 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 737 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 152-participant average among 4 other Agitation,Psychomotor trials with a reported enrollment target (385% higher). The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Agitation,Psychomotor appearing as the primary indexed condition, and to 4 interventions - of which Haloperidol Injection is the first listed.
NCT03211897 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03211897 about?
NCT03211897 is a clinical study titled "Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation". The goal of this research investigation is to conduct a prospective observational study of the comparative efficacy of haloperidol versus olanzapine versus midazolam versus ziprasidone for the treatment of acute undifferentiated agitation in the emergency department.
What is the current status of trial NCT03211897?
This trial is currently completed. The enrollment target is 737 participants. The study started on 2017-06-15. Estimated completion is 2017-10-01.
What conditions does trial NCT03211897 study?
This clinical trial studies the following conditions: Agitation,Psychomotor.
What interventions are being tested in trial NCT03211897?
The interventions under investigation include: Haloperidol Injection (DRUG), Ziprasidone Injection (DRUG), OLANZapine Injection (DRUG), Midazolam injection (DRUG).
Who is sponsoring clinical trial NCT03211897?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03211897 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Agitation,Psychomotor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial on Agitation in Alzheimer's Dementia
RECRUITING · Phase 2
-
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
RECRUITING · Early Phase 1
-
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
RECRUITING · NA
-
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.